Prime Medicine (PRME)
Market Price (5/17/2026): $2.98 | Market Cap: $527.7 MilSector: Health Care | Industry: Biotechnology
Prime Medicine (PRME)
Market Price (5/17/2026): $2.98Market Cap: $527.7 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. | Weak multi-year price returns2Y Excs Rtn is -90%, 3Y Excs Rtn is -158% Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 17% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -207 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -5122% Expensive valuation multiplesP/SPrice/Sales ratio is 129x Weak revenue growthRev Chg QQuarterly Revenue Change % is -41% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 700% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -3877%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -3935% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -42% High stock price volatilityVol 12M is 104% Significant short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 18.65 Key risksPRME key risks include [1] a limited cash runway raising substantial doubt about its ability to continue as a going concern and [2] high dependency on its novel Prime Editing technology, Show more. |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -90%, 3Y Excs Rtn is -158% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 17% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -207 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -5122% |
| Expensive valuation multiplesP/SPrice/Sales ratio is 129x |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -41% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 700% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -3877%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -3935% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -42% |
| High stock price volatilityVol 12M is 104% |
| Significant short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 18.65 |
| Key risksPRME key risks include [1] a limited cash runway raising substantial doubt about its ability to continue as a going concern and [2] high dependency on its novel Prime Editing technology, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Prime Medicine reported a significant miss on Q1 2026 earnings and revenue.
The company announced a quarterly loss of $0.28 per share, missing the Zacks Consensus Estimate of a $0.24 loss per share by -15.99%. Additionally, Prime Medicine's revenues for the quarter ended March 2026 were $0.86 million, falling short of the Zacks Consensus Estimate by 45.13%. The company has not met consensus revenue estimates in the last four quarters.
2. The company experienced a decline in its cash position and continued to report a net loss.
Prime Medicine's cash, cash equivalents, and investments decreased from $191.4 million as of December 31, 2025, to $149.2 million as of March 31, 2026. Concurrently, the company reported a net loss of $49.1 million for the first quarter of 2026. While the company expects its cash runway to extend into 2027 under current operating plans, the reduction in cash and ongoing losses can impact investor confidence.
Show more
Stock Movement Drivers
Fundamental Drivers
The -23.1% change in PRME stock from 1/31/2026 to 5/16/2026 was primarily driven by a -32.5% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312026 | 5162026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.81 | 2.93 | -23.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 6 | 4 | -32.5% |
| P/S Multiple | 102.3 | 128.6 | 25.7% |
| Shares Outstanding (Mil) | 161 | 177 | -9.4% |
| Cumulative Contribution | -23.1% |
Market Drivers
1/31/2026 to 5/16/2026| Return | Correlation | |
|---|---|---|
| PRME | -23.1% | |
| Market (SPY) | 7.1% | 52.4% |
| Sector (XLV) | -5.8% | 42.9% |
Fundamental Drivers
The -40.7% change in PRME stock from 10/31/2025 to 5/16/2026 was primarily driven by a -27.1% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 10312025 | 5162026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.94 | 2.93 | -40.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 5 | 4 | -18.7% |
| P/S Multiple | 128.6 | 128.6 | 0.0% |
| Shares Outstanding (Mil) | 129 | 177 | -27.1% |
| Cumulative Contribution | -40.7% |
Market Drivers
10/31/2025 to 5/16/2026| Return | Correlation | |
|---|---|---|
| PRME | -40.7% | |
| Market (SPY) | 9.0% | 34.4% |
| Sector (XLV) | 1.4% | 25.1% |
Fundamental Drivers
The 69.4% change in PRME stock from 4/30/2025 to 5/16/2026 was primarily driven by a 69.4% change in the company's P/S Multiple.| (LTM values as of) | 4302025 | 5162026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.73 | 2.93 | 69.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3 | 4 | 35.2% |
| P/S Multiple | 75.9 | 128.6 | 69.4% |
| Shares Outstanding (Mil) | 131 | 177 | -26.1% |
| Cumulative Contribution | 69.4% |
Market Drivers
4/30/2025 to 5/16/2026| Return | Correlation | |
|---|---|---|
| PRME | 69.4% | |
| Market (SPY) | 34.8% | 26.8% |
| Sector (XLV) | 5.1% | 25.4% |
Fundamental Drivers
The -78.7% change in PRME stock from 4/30/2023 to 5/16/2026 was primarily driven by a null change in the company's P/S Multiple.| (LTM values as of) | 4302023 | 5162026 | Change |
|---|---|---|---|
| Stock Price ($) | 13.77 | 2.93 | -78.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 4 | 9.2233720368547763E17% |
| P/S Multiple | ∞ | 128.6 | |
| Shares Outstanding (Mil) | 97 | 177 | -45.1% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2023 to 5/16/2026| Return | Correlation | |
|---|---|---|
| PRME | -78.7% | |
| Market (SPY) | 84.7% | 33.7% |
| Sector (XLV) | 14.2% | 30.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| PRME Return | 0% | -62% | -52% | -67% | 19% | -10% | -94% |
| Peers Return | 1% | -59% | 6% | -49% | 21% | 22% | -67% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 100% |
Monthly Win Rates [3] | |||||||
| PRME Win Rate | 0% | 8% | 42% | 33% | 25% | 60% | |
| Peers Win Rate | 35% | 35% | 48% | 33% | 56% | 50% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| PRME Max Drawdown | 0% | -69% | -74% | -72% | -66% | -33% | |
| Peers Max Drawdown | -58% | -65% | -51% | -66% | -60% | -32% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: BEAM, CRSP, NTLA, EDIT.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/15/2026 (YTD)
How Low Can It Go
| Event | PRME | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -65.0% | -18.8% |
| % Gain to Breakeven | 185.7% | 23.1% |
| Time to Breakeven | 90 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -25.9% | -7.8% |
| % Gain to Breakeven | 35.0% | 8.5% |
| Time to Breakeven | 406 days | 18 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -13.8% | -19.2% |
| % Gain to Breakeven | 16.0% | 23.8% |
| Time to Breakeven | 79 days | 105 days |
In The Past
Prime Medicine's stock fell -65.0% during the 2025 US Tariff Shock. Such a loss loss requires a 185.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | PRME | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -65.0% | -18.8% |
| % Gain to Breakeven | 185.7% | 23.1% |
| Time to Breakeven | 90 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -25.9% | -7.8% |
| % Gain to Breakeven | 35.0% | 8.5% |
| Time to Breakeven | 406 days | 18 days |
In The Past
Prime Medicine's stock fell -65.0% during the 2025 US Tariff Shock. Such a loss loss requires a 185.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Prime Medicine (PRME)
AI Analysis | Feedback
```htmlHere are two analogies to describe Prime Medicine:
- Prime Medicine is like CRISPR Therapeutics, but with a gene-editing technology designed to fix a wider variety of genetic errors.
- Prime Medicine is like Beam Therapeutics, but with a gene-editing tool capable of correcting a much broader range of genetic mutations beyond just single-base changes.
AI Analysis | Feedback
- Prime Editing Technology: A proprietary gene editing platform designed to precisely correct diverse genetic mutations underlying human diseases.
- Genetic Therapies: A pipeline of one-time curative treatments in development, utilizing Prime Editing to address a wide spectrum of human diseases.
AI Analysis | Feedback
For the public company Prime Medicine (symbol: PRME), the provided description indicates that it is a biotechnology company in the research and development phase. It is focused on developing "Prime Editors," a new class of genetic therapies for human diseases. The technology "is not yet clinically validated for human therapeutic use." Based on this information, Prime Medicine does not currently have major customers, either other companies or individuals, as its therapies are not yet commercialized or approved for sale. Its primary activities are the development of its gene editing technology and pipeline programs.Based on the provided company description, Prime Medicine (PRME) is a biotechnology company in the research and development phase. Its core focus is on developing a new class of genetic therapies, Prime Editors. The description explicitly states that this technology "is not yet clinically validated for human therapeutic use."
Therefore, Prime Medicine does not currently have major customers, whether they be other companies or individual patients, as its products are not yet commercialized or approved for sale. The company is actively developing its therapeutic pipeline rather than selling existing products or services.
AI Analysis | Feedback
Broad InstituteAI Analysis | Feedback
Allan Reine, MD Chief Executive Officer
- Allan Reine, MD, was appointed Chief Executive Officer of Prime Medicine in May 2025, having previously served as the company's Chief Financial Officer since joining in January 2024.
- He concurrently serves as the principal financial officer.
- Prior to Prime Medicine, Dr. Reine held CFO roles at Foghorn Therapeutics and Pieris Pharmaceuticals.
- He also serves as Chairman of the Board of ONK Therapeutics.
- Earlier in his career, he managed various healthcare portfolios, focusing on biotechnology and pharmaceutical companies, at firms such as Lombard Odier Asset Management, Citi Principal Strategies, SAC Capital, Trivium Capital, and Alexandra Investment Management.
- He began his career in biotechnology investment banking and equity research at CIBC World Markets.
Mohammed Asmal, MD, PhD Chief Medical Officer
- Mohammed Asmal, MD, PhD, is the Chief Medical Officer at Prime Medicine.
- He is a physician-scientist with an AB in biology and biomedical engineering from Harvard University and an MD-PhD in molecular and cellular biology from Columbia University.
- Dr. Asmal trained in internal medicine and infectious diseases at the Brigham and Women's and Massachusetts General Hospitals.
- He previously led trials in oncology and hepatitis C at Vertex Pharmaceuticals, advancing multiple small molecules into the clinic through Phase II.
- Subsequently, he led the clinical development team at bluebird bio, overseeing lentiviral-based gene therapy programs that led to the first approval of a gene therapy for a hemoglobinopathy.
Matthew Hawryluk, PhD Chief Business Officer
- Matthew Hawryluk, PhD, joined Prime Medicine as Chief Business Officer in 2025.
- Before joining Prime Medicine, he served as Chief Business Officer at AIRNA Corporation, an RNA-editing company, where he was responsible for corporate and business development, finance, and legal functions, and helped secure an oversubscribed $155 million Series B financing.
- For nearly a decade, Dr. Hawryluk was Executive Vice President and Chief Business Officer, Head of Legal, and Boston Site Head at Gritstone bio, Inc. (NASDAQ: GRTS), guiding its growth from an early-stage company to a public entity and spearheading its expansion into infectious diseases.
- He has led transactions exceeding $2.5 billion in potential value, including collaborations with Gilead Sciences and bluebird bio.
Ann Lee, PhD Chief Technical Officer
- Ann Lee, PhD, is the Chief Technical Officer of Prime Medicine.
- She is a biotech executive with extensive experience in the development and manufacturing of vaccines, biologics, small molecules, and cell therapies.
- Dr. Lee has contributed to the licensure and commercialization of 25 new vaccines and medicines, most recently including two CAR T cell therapies during her time at BMS, following its acquisitions of Celgene and Juno Therapeutics.
Niamh Alix Chief Human Resources Officer
- Niamh Alix joined Prime Medicine in June 2022 as Chief Human Resources Officer.
- She brings nearly two decades of experience in human resources, focusing on growing teams from small, early-stage organizations to global enterprises.
- Ms. Alix holds a master's degree in HR strategies from Dublin City University and a B.Sc. in management from the Technological University of Dublin.
AI Analysis | Feedback
Key Risks to the Business of Prime Medicine (PRME)
- Lack of Clinical Validation for Prime Editing Technology: Prime Medicine's core Prime Editing technology is a novel gene editing platform that has not yet been clinically validated for human therapeutic use. The entire business model relies on the successful development and regulatory approval of this unproven technology.
- Dependence on Licensed Intellectual Property from Broad Institute: Prime Medicine's ability to operate and protect its Prime Editing platform is highly dependent on an exclusive license agreement with the Broad Institute. The Broad Institute owns key patents, including the '770 Patent, covering the Prime Editing technology. Any issues with this license, its terms, or the Broad Institute's ownership and enforcement of the underlying patents could severely impact Prime Medicine's business.
- Potential Conflicts of Interest with Co-Founder: A co-founder, Dr. David Liu, has ongoing consulting commitments that accommodate a previous commitment with Beam Therapeutics Inc., which could result in or may create the appearance of a conflict of interest for Prime Medicine.
AI Analysis | Feedback
A clear emerging threat is posed by **Beam Therapeutics Inc.** (BEAM). Dr. David Liu, a co-founder of Prime Medicine, also has a "previous commitment with respect to Beam Therapeutics Inc., which could result in or may create the appearance of a conflict of interest." Beam Therapeutics is an established biotechnology company in the gene editing space. This dual affiliation with a key scientific leader suggests an ongoing competitive dynamic where advancements by Beam Therapeutics in gene editing technology or their pipeline programs could directly challenge Prime Medicine's market position, especially given Prime Medicine's claim of superior versatility and precision over existing gene editing platforms.
AI Analysis | Feedback
Prime Medicine (Nasdaq: PRME) is focused on developing one-time curative genetic therapies through its proprietary Prime Editing technology, which aims to address a wide spectrum of diseases caused by genetic mutations.
The addressable market for Prime Medicine's core Prime Editing technology is substantial. Globally, the prime editing market size reached approximately $258.4 million in 2024. This market is projected to experience robust expansion, with a compound annual growth rate (CAGR) of 37.2% from 2025 to 2033, reaching a forecasted value of approximately $3.52 billion by the end of 2033. North America held the largest share of this market in 2024, valued at about $112.6 million. The Asia Pacific region is also a rapidly growing market for prime editing, with a value of approximately $52.1 million in 2024.
Beyond the core technology, Prime Medicine is developing therapies for specific diseases, each with its own addressable market:
- For Chronic Granulomatous Disease (CGD), Prime Medicine's lead ex vivo therapy (PM359) targets a market projected to grow from $1.44 billion in 2025 to $2.2 billion by 2035.
- For Wilson Disease, the six most common mutations account for up to 26,000 patients in addressable markets, including the U.S., Europe, and Japan.
- The in vivo programs targeting Alpha-1 Antitrypsin Deficiency (AATD) are expected to reach a market of $4.4 million by 2035.
AI Analysis | Feedback
Prime Medicine (PRME) is a biotechnology company in the pre-revenue stage from product sales, with its future revenue growth over the next 2-3 years primarily driven by advancements in its gene editing pipeline and strategic collaborations. Key drivers include:
-
Achievement of Preclinical and Clinical Milestones: A significant driver of future revenue will be the successful advancement of Prime Medicine's pipeline programs through preclinical and clinical development. This includes the planned Investigational New Drug (IND) and/or Clinical Trial Application (CTA) filings for its liver-focused programs for Wilson's Disease (PM577) in the first half of 2026 and Alpha-1 Antitrypsin Deficiency (AATD) in mid-2026, with initial clinical data for both anticipated in 2027. These milestones are critical for triggering payments from existing collaborations and attracting new partners.
-
Expansion and Initiation of Strategic Collaborations: Prime Medicine's revenue growth is heavily reliant on strategic partnerships, such as its ongoing collaboration with Bristol Myers Squibb to develop and commercialize Prime Edited ex vivo T-cell therapies. These agreements typically include upfront payments, research funding, and milestone payments upon the achievement of specific development, regulatory, and commercial targets. The company actively seeks additional business development opportunities to leverage its Prime Editing platform across a broader range of indications.
-
Advancement of the Cystic Fibrosis Program: The company is progressing an in vivo Cystic Fibrosis program, supported by funding from the Cystic Fibrosis Foundation. Anticipated generation of preclinical proof-of-concept data in 2026 could attract further funding, partnerships, or lead to milestone payments, contributing to revenue growth.
-
Monetization of the Chronic Granulomatous Disease (CGD) Program: Although Prime Medicine has strong Phase 1/2 clinical data for PM359 in Chronic Granulomatous Disease (CGD) and intends to submit a Biologics License Application (BLA), the company has indicated it is exploring options for external clinical development due to the small patient population and high costs associated with independent commercialization. This suggests potential future revenue through out-licensing, co-development agreements, or other partnerships for PM359.
AI Analysis | Feedback
Share Issuance
Prime Medicine raised approximately $175.0 million in gross proceeds from its initial public offering (IPO) in October 2022, by selling 10.3 million shares of common stock at $17.00 per share. In August 2025, the company completed a public offering of 43.7 million shares of common stock at $3.30 per share, generating approximately $144.2 million in gross proceeds. Additionally, in February 2024, Prime Medicine raised around $150.9 million through a public offering of common stock and pre-funded warrants.Inbound Investments
The company launched in July 2021 with $315 million in private financing prior to its IPO. The Cystic Fibrosis Foundation agreed to provide up to $24 million in additional funding to accelerate the development of Prime Editors for cystic fibrosis, with $6.0 million of this received in the third quarter of 2025. Furthermore, BMS made a $55 million investment in Prime Medicine in September 2024.Capital Expenditures
Prime Medicine reported capital expenditures of $290K in Q4 2025, allocated to long-term assets and infrastructure. For the last 12 months as of Q4 2025, capital expenditures totaled approximately $4.5 million. These expenditures are primarily focused on advancing its gene editing platform and therapeutic programs, including license and intellectual property costs and facility-related expenses. The company expects its cash and investments as of December 31, 2025, to be sufficient to fund operating expenses and capital expenditure requirements into 2027.Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Prime Medicine Earnings Notes | 12/16/2025 | |
| Is Prime Medicine Stock Built to Withstand More Downside? | 10/17/2025 | |
| Prime Medicine (PRME) EBITDA Comparison | 08/08/2025 | |
| Prime Medicine (PRME) Operating Cash Flow Comparison | 08/08/2025 | |
| Prime Medicine (PRME) Debt Comparison | 08/08/2025 | |
| Prime Medicine (PRME) Tax Expense Comparison | 08/08/2025 | |
| Prime Medicine (PRME) Net Income Comparison | 08/08/2025 | |
| Prime Medicine (PRME) Revenue Comparison | 08/08/2025 | |
| Prime Medicine (PRME) Operating Income Comparison | 08/08/2025 | |
| Prime Medicine (PRME) Valuation Ratios Comparison | 08/08/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to PRME.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 10312022 | PRME | Prime Medicine | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | -25.6% | -65.5% | -70.3% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 13.67 |
| Mkt Cap | 1.6 |
| Rev LTM | 39 |
| Op Inc LTM | -372 |
| FCF LTM | -364 |
| FCF 3Y Avg | -301 |
| CFO LTM | -363 |
| CFO 3Y Avg | -287 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.0% |
| Rev Chg 3Y Avg | 32.4% |
| Rev Chg Q | -24.4% |
| QoQ Delta Rev Chg LTM | -3.4% |
| Op Inc Chg LTM | 13.7% |
| Op Inc Chg 3Y Avg | -16.1% |
| Op Mgn LTM | -636.6% |
| Op Mgn 3Y Avg | -935.8% |
| QoQ Delta Op Mgn LTM | 15.1% |
| CFO/Rev LTM | -549.5% |
| CFO/Rev 3Y Avg | -715.9% |
| FCF/Rev LTM | -550.2% |
| FCF/Rev 3Y Avg | -727.1% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.6 |
| P/S | 24.5 |
| P/Op Inc | -3.9 |
| P/EBIT | -3.9 |
| P/E | -4.1 |
| P/CFO | -4.5 |
| Total Yield | -24.4% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -30.5% |
| D/E | 0.1 |
| Net D/E | -0.3 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -13.1% |
| 3M Rtn | 0.0% |
| 6M Rtn | 0.8% |
| 12M Rtn | 60.8% |
| 3Y Rtn | -68.8% |
| 1M Excs Rtn | -18.3% |
| 3M Excs Rtn | -8.3% |
| 6M Excs Rtn | -11.1% |
| 12M Excs Rtn | 47.8% |
| 3Y Excs Rtn | -148.8% |
Price Behavior
| Market Price | $2.93 | |
| Market Cap ($ Bil) | 0.5 | |
| First Trading Date | 11/12/2015 | |
| Distance from 52W High | -56.1% | |
| 50 Days | 200 Days | |
| DMA Price | $3.56 | $4.02 |
| DMA Trend | indeterminate | down |
| Distance from DMA | -17.7% | -27.0% |
| 3M | 1YR | |
| Volatility | 69.1% | 101.8% |
| Downside Capture | 278.68 | 255.34 |
| Upside Capture | 149.68 | 260.34 |
| Correlation (SPY) | 44.5% | 26.9% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.99 | 2.44 | 2.69 | 2.23 | 2.29 | 2.07 |
| Up Beta | 3.37 | 3.06 | 3.47 | 2.71 | 2.30 | 1.60 |
| Down Beta | 2.71 | 0.93 | 1.43 | 1.67 | 1.70 | 2.18 |
| Up Capture | 157% | 160% | 277% | 219% | 617% | 855% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 12 | 21 | 33 | 59 | 117 | 337 |
| Down Capture | 402% | 310% | 254% | 200% | 168% | 113% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 10 | 22 | 31 | 66 | 131 | 404 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PRME | |
|---|---|---|---|---|
| PRME | 96.2% | 102.3% | 1.11 | - |
| Sector ETF (XLV) | 14.8% | 14.9% | 0.71 | 24.5% |
| Equity (SPY) | 27.4% | 12.1% | 1.71 | 29.7% |
| Gold (GLD) | 42.5% | 26.8% | 1.30 | 11.5% |
| Commodities (DBC) | 45.4% | 18.5% | 1.88 | -2.3% |
| Real Estate (VNQ) | 11.5% | 13.5% | 0.56 | 20.0% |
| Bitcoin (BTCUSD) | -23.7% | 41.8% | -0.54 | 21.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PRME | |
|---|---|---|---|---|
| PRME | -31.2% | 89.2% | -0.20 | - |
| Sector ETF (XLV) | 4.8% | 14.7% | 0.15 | 30.6% |
| Equity (SPY) | 13.6% | 17.1% | 0.63 | 34.4% |
| Gold (GLD) | 19.4% | 17.9% | 0.88 | 10.6% |
| Commodities (DBC) | 10.9% | 19.4% | 0.45 | 7.2% |
| Real Estate (VNQ) | 2.9% | 18.8% | 0.06 | 32.5% |
| Bitcoin (BTCUSD) | 7.2% | 55.9% | 0.34 | 20.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PRME | |
|---|---|---|---|---|
| PRME | -15.8% | 64.6% | -0.12 | - |
| Sector ETF (XLV) | 9.6% | 16.5% | 0.47 | 25.0% |
| Equity (SPY) | 15.5% | 17.9% | 0.74 | 30.2% |
| Gold (GLD) | 13.0% | 16.0% | 0.67 | 8.9% |
| Commodities (DBC) | 8.3% | 17.9% | 0.38 | 7.1% |
| Real Estate (VNQ) | 5.0% | 20.7% | 0.21 | 29.3% |
| Bitcoin (BTCUSD) | 67.4% | 66.9% | 1.06 | 10.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/3/2026 | -9.2% | -11.8% | -25.3% |
| 11/7/2025 | -8.9% | -20.3% | 0.2% |
| 7/30/2025 | -4.6% | 3.8% | -12.2% |
| 2/28/2025 | 4.1% | -5.0% | -17.8% |
| 11/12/2024 | -8.3% | -26.6% | -30.3% |
| 8/8/2024 | -0.2% | -6.6% | -19.3% |
| 5/10/2024 | -1.9% | 23.1% | 34.3% |
| 3/1/2024 | 1.3% | -5.7% | -21.7% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 3 | 2 | 3 |
| # Negative | 8 | 9 | 8 |
| Median Positive | 1.3% | 13.5% | 0.6% |
| Median Negative | -4.3% | -11.8% | -20.5% |
| Max Positive | 4.1% | 23.1% | 34.3% |
| Max Negative | -9.2% | -26.6% | -30.3% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 03/03/2026 | 10-K |
| 09/30/2025 | 11/07/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 02/28/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/10/2024 | 10-Q |
| 12/31/2023 | 03/01/2024 | 10-K |
| 09/30/2023 | 11/03/2023 | 10-Q |
| 06/30/2023 | 08/07/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/09/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 10/21/2022 | 424B4 |
Recent Forward Guidance [BETA]
Latest: Q1 2026 Earnings Reported 5/7/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2027 Cash Runway | Affirmed | Guidance: 2,027 for 2027 | |||||
Prior: Q4 2025 Earnings Reported 3/3/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2027 Cash Runway | 2,027 | ||||||
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Gv, 2021 Gp, Llc | GV 2021, L.P. | Buy | 8052025 | 3.30 | 1,500,000 | 4,950,000 | 10,766,052 | Form | |
| 2 | Nelsen, Robert | ARCH Venture Fund XII, L.P. | Buy | 8012025 | 3.30 | 3,030,300 | 9,999,990 | 20,559,990 | Form | |
| 3 | Arch, Venture Partners Xii, Llc | ARCH Venture Fund XII, L.P. | Buy | 8012025 | 3.30 | 3,030,300 | 9,999,990 | 20,559,990 | Form | |
| 4 | Arch, Venture Partners X, Llc | ARCH Venture Fund XII, L.P. | Buy | 8012025 | 3.30 | 3,030,300 | 9,999,990 | 20,559,990 | Form | |
| 5 | Liu, David R | Direct | Buy | 7012025 | 2.52 | 21,000 | 52,830 | 50,920,145 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.